Raymond James Financial
HUMA icon

Raymond James Financial’s Humacyte HUMA Stock Holding History

Raymond James Financial’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.3K Sell
48,329
-3,000
-6% -$3.12K ﹤0.01% 5176
2025
Q4 		$49.3K Sell
51,329
-20,799
-29% -$29.5K ﹤0.01% 5012
2025
Q3 		$126K Buy
72,128
+61,017
+549% +$120K ﹤0.01% 4713
2025
Q2 		$23.2K Sell
11,111
-6,856
-38% -$13.2K ﹤0.01% 5537
2025
Q1 		$30.6K Sell
17,967
-56,731
-76% -$213K ﹤0.01% 4683
2024
Q4 		$377K Buy
+74,698
New +$370K ﹤0.01% 4058

Other funds holding HUMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Raymond James Financial's HUMA Position: Q1 2026 in Review

Raymond James Financial reduced its Humacyte (HUMA) stake by 5.8% in Q1 2026, selling an estimated $3.12K and leaving 48,329 shares worth $29.3K. The position accounts for ﹤0.01% of the portfolio, ranked #5176.

Raymond James Financial first reported a position in HUMA in Q4 2024 and has held it in 6 quarters since. The position peaked at $377K in Q4 2024. 159 funds tracked by Wall St. Rank hold HUMA as of Q1 2026.

  • Raymond James Financial held 48,329 shares of Humacyte worth $29.3K as of Q1 2026.
  • Raymond James Financial sold 3,000 Humacyte shares in Q1 2026, an estimated $3.12K.
  • Humacyte made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5176 holding.
  • Raymond James Financial first reported a position in Humacyte in Q4 2024 and has held it in 6 quarters since.
  • Raymond James Financial's Humacyte position peaked at $377K in Q4 2024.
  • 159 funds tracked by Wall St. Rank held Humacyte as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.